Table 3.
Clinical trials exploring ncRNAs as biomarkers of treatment response
| Study Type | Conditions | Treatment | ncRNA | Sample type | Trial status | Trail identifier |
|---|---|---|---|---|---|---|
| Observational | Breast cancer | Chemotherapy ± hormone therapy | Circulating miRNA | Blood | Active, not yet recruiting | NCT01722851 |
| Observational | Breast cancer | Hormone therapy | miRNA | Tissue | NA | NCT02950207 |
| Observational | Metastatic breast cancer | Bevacizumab | miRNA | Blood | Terminated | NCT01598285 |
| Interventional | TNBC | Epirubicin-cyclophosphamide plus paclitaxel-carboplatin | Circulating miRNA | Serum | Not yet recruiting | NCT04771871 |
| Observational | Esophageal cancer | Chemotherapy/radiotherapy | Circulating miRNA | Plasma | Active, not yet recruiting | NCT02812680 |
| Observational | GC | Capecitabine + cisplatin or capecitabine + oxaliplatin+/− trastuzumab | miRNA | Tissue and blood | Recruiting | NCT03253107 |
| Observational | Medullary thyroid cancer | Vandetanib | miRNA | Tissue, blood | NA | NCT02268734 |
| Observational | Prostate cancer | Androgen deprivation therapy | Exosomal miRNAs | Blood | Active, not yet recruiting | NCT02366494 |
| Interventional | Metastatic castration-resistant prostate cancer | Androgen receptor target agents/LHRH agonist | Circulating miRNA | Blood | Recruiting | NCT04188275 |
| Interventional | Metastatic castration-resistant prostate cancer | Chemotherapy/novel hormonal agent | miRNA | Blood | Recruiting | NCT04662996 |
| Interventional | NSCLC | Radiotherapy | miRNA | Plasm | NA | NCT03074175 |
| Observational | Ovarian cancer | Chemotherapy | miRNA | Plasma, urine, tumor samples | Active, not yet recruiting | NCT02758652 |
| Observational | Pancreatic cancer | NA | miRNA | Serum | Recruiting | NCT04406831 |
| Observational | Pancreaticobiliary cancers | Surgery/chemotherapy | CircRNA | Plasm | Recruiting | NCT04584996 |
| Observational | Rectal cancer | Neoadjuvant chemoradiotherapy | miRNA | Blood | Recruiting | NCT03962088 |
| Interventional | EGFR-driven advanced solid tumors | Dacomitinib | LncRNA | NA | Not yet recruiting | NCT04946968 |
EGFR Epidermal growth factor receptor, GC Gastric cancer, LHRH Luteinizing hormone-releasing hormone, NSCLC Non-small cell lung cancer, TNBC Triple-negative breast cancer.